Диссертация (1173282), страница 20
Текст из файла (страница 20)
Oancea, A. Mangrau // Liver Dis. - 2011. - № 20(2). Р. 181-189.102. Bouvry, C. Transarterial Radioembolization (TARE) Agents beyond 90YMicrospheres / C. Bouvry, X. Palard, J. Edeline, V. Ardisson, P. Loyer, E. Garin,N. Lepareur // Biomed Res Int. - 2018. - 2018:1435302.103. Bruix, J. Adjurvant sorafenib for hepatocellular carcinoma after resection orablation (STORM); a phase 3, randomised, double-blind, placebo-controlled trial /J.
Bruix, T. Takayama, V. Mazaferro // Lancet Oncol. - 2015. - № 16(13). - Р. 13441354.104. Carlin, S.P. Dissemination of hepatocellular car-cinoma in subcutaeous tissueafter fine needle aspiration cytology (FNAC) / S.P. Carlin, A. García-Botella,L. Diez-Valladares,E. Perez-Aguirre,L. Ortega,R. Mendez,A.J. Torres//Hepatogastroenterology.
- 2013. - № 60(128). - Р. 1839-1840.105. Chonq, D.Q. The landscape of targeted therapies for cholangiocarcinoma: currentstatus and emerging targets. / D.Q. Chong, A.X. Zhu // Oncotarget. - 2016. - 7(29), - P.46750-46767.106. Chunq, V.Systemictherapyforhepatocellularcarcinomaandcholangiocarcinoma / V. Chunq // Surg Oncol Clin N Am. - 2015. - 24(1). - С. 187-98.107. Diaz-Gonzalez, Al.
Treatment of Hepatocellular Carcinoma / Al. Diaz-Gonzalez,M. Reig, J. Bruix // Dig Dis. - 2016. - №34(5). - P. 597-602.108. Dindo, D. Classificationofsurgical complications. A new proposal withevaluation in a cohort of 6336 patients and results of a survey / D.
Dindo,N. Demartines, P.A. Clavien // Ann Surg. - 2004. - 240. - Р. 205-218.109. Doussot, A.Outcomes after Resection of Intrahepatic Cholangiocarcinoma:External Validation and Comparison of Prognostic Models / A. Doussot, B. GrootKoerkamp, J.K. Wiggers, J. Chou, M. Gonen, R.P. DeMatteo, P.J. Allen, T.P. Kingham,M.I. D’Angelica, W.R. Jarnagin // Journal of the American College of Surgeons . –1312015.
- V.221, №2. - P. 452–461.110. Elgindy, N. Highdose percutaneous ethanol injection therapy of liver tumors:Patient acceptance and complications / N. Elgindy, H. Lindholm, P. Gunvén // ActaRadiologica. - 2000. - V.41, № 5. - Р. 458-504.111. Elshamy, J. Hepatocellular carcinoma beyond Milan criteria: Managenemt andtransplant selection criteria / J.Elshamy et al. // World J Hepatol. - 2016.
- № 8(21). –Р. 874-880.112. Ferlay, J. Cancer incidence and mortality worldwide: Sources, methods and majorpatterns in GLOBOCAN in 2012 / J. Ferlay, I. Soerjomataran, R. Dikshit, S. Eser,C. Mathers et al. // Int. J.Cancer. - 2015. - № 136 (5). - Р. 359-386.113. Fukumitsu, N. Radiotherapy for liver cancer / N. Fukumitsu, T. Okumura,H. Sakurai // J of General and Family Medicine. - 2017. - V.18. - P. 126-130.114. Ginsburg, M. Comparison of Combination Therapies in the Management ofHepatocellular Carcinoma: Transarterial Chemoembolization with RadiofrequencyAblation / M.
Ginsburg, S.P. Zivin, R. Wroblewski et al. // Radiology Juornal ofVascular and Interventional. - 2015. - V.26, № 3. - P. 330-341.115. Gu, O. Effecacyandsafetyoflivertransplantationinpatients withcholangiocarcinoma: A systematic review and meta-analysis / O. Gu, J. Bai, X. Shi,J. Zhou, Y. Qui, Y. Wu, C. Jiang, X. Sun, F. Xu, Y. Zhang, Y.
Ding // InternationalJournal of Cancer . - 2012. - V. 130(9). - P. 2155-2163.116. Han, K. Radiofrequency ablation in the treatment of unresectable intrahepaticcholangiocarcinoma: systematic review and meta-analysis / K. Han, H.K. Ko,K.W. Kim, H.J. Won, Y.M. Sbin, P.N. Kim // J Vasc Interv Radiol. - 2015. - V.26, №7.- P. 943-951.117. He, W. The role of clinically significant portal hypertension in hepaticresection for hepatocellular carcinoma patients: a propensity score matching analysis /W. He, Q. Zeng , Y. Zheng, M.
Chen, J. Shen, J. Qiu, M. Chen, R. Zou, Y. Liao, Q. Li,X. Wu, B. Li, Y. Yuan // BMC Cancer. - 2015. - № 15. - Р. 263.118. Hinabaw, J.L. Percutaneous tumor ablation tools: microwave, radiofrequency, orcryoablation – what should you use why? / J.L. Hinabaw, M.G. Lubner, C.L.
Brace,132T.J. Ziemlewicz // Radiographics. - 2014. - V.34, № 5. - P. 1344-1366.119. Huang, K.Doxorubicinelutingbeadsversusconventionaltransarterialchemoembolization for the treatment of hepatocallular carcinoma / K. Huang, Q. Zhouet al.// J Gastroenterol Hepatol. - 2014. - № 29. - P. 920-625.120. Isayama, H. Clinical benefit of radiation therapy and metallic stenting forunresectable hilar cholangiocarcinoma / H.
Isayama, T. Tsujino, Y. Nakai, T. Sasaki,K. Nakagawa, H. Yamashita, T. Aoki, K. Koike // Wld J. Gastroenterol. - 2012. №18(19). - P. 2364–2370.121. Jerjir, N. Intravoxel incoherent motion and dynamic contrast-enhanced MRI fordifferentiation between hepatocellular adenoma and focal nodular hyperplasia. /N. Jerjir, L. Bruyneel, M. Haspeslaqh, S. Quenet, K. Coenegrachts// Radiology. -2017. - 90(1076): 20170007.122. Kanq, T.W.
Percutaneous ablation for perivascular hepatocellular carcinoma:Refining the current status based on emerging evidence and future perspectives /T.W. Kanq, H.K. Lim, D.I. Cha // World J Gasteroenterol. - 2018. - 24(47). - P. 53315337.123. Kelly, D. Hepatocellularcarcinomainchildren / D. Kelly,K. Sharif,R.V. Brown, B. Morland // Clin Liver Dis. - 2015.
- 19(2). - P. 433-480.124. Lefkowitch, J.H. Scheuer's Liver Biopsy Interpretation // Amsterdam: Publisher:Elisevier; 9 edition. - 2015. - P. 440.125. Lencioni, R.Image-QuidedAblationRecommendations for Clinical Validation ofTechnologies – A Western Perspective/ofMalignantLiverTomors:Novel Thermal and Non-ThermalR.
Lencioni, T. de Baere, R.C. Martin,C.W. Nutting, G. Narayanan // Liver Cancer. - 2015. - Vol. 4, №4. - P. 208-214.126. Li, D. Locally ablative therapies for primary and metastatic liver cancer / D. Li,J. Kang, D. Madoff // Expert Rev. Anticancer Ther. - 2014. - 14 (8). - P. 931-945.127. Li, S. Genetic polymorphism of interleukin-16 influences susceptibility to HBVrelated hepatocellular carcinoma in a Chinese population / S. Li , Y. Deng, Z.P. Chen,S. Huang, X.C. Liao, L.W. Lin et al. // Infection, Genetics and Evolution.
- 2011. - 11(8). - Р. 2083-2088.133128. Llovet, J.M. Hepatocellular carcinoma / J.M. Llovet, A. Burroughs, J. Bruix //Lancet. - 2003. - V.362, № 9399. - P. 1907–1917.129. Lopez, K.T. Consequences of needle tract seeding of hepatocellular cancer afterliver transplant / K.T. Lopez, S.K. Kuwada, L.L. Wong // Clin Transplant.
- 2013. - 27(4). - Р. 400-406.130. Lubner, M.G. Microwave tumor ab-lation: mechanism of action, clinical result,and devices / M.G. Lubner, C.L. Brace, J.L. Hinsbaw, F.T. Lee // J Vasc Interv Radiol. 2010. - V.21, № 8. - Р. 192-203.131. Lumley, S.F. Hepatitis B Virus Adaptation to the CD8+ T Cell Response:Consequences for Host and Pathogen / S.F. Lumley, A.L. McNauqhton, P. Klenerman,K.A. Lythqoe, P.C. Matthews // Front Immunol. - 2018. - 16(9). - Р. 1561.132. Lyu, S. Diagnosis and therapy of primary undifferentiated embryonal sarcoma ofthe liver / S. Lyu, X. Shi, Y. Liang et al.
// Chin Med J (Engl). - 2014. - 127 (8). Р. 1585-1587.133. Mavros, M.N. Treatment andCholangiocarcinoma: SystematicPrognosisReviewandforPatientswithIntrahepaticMeta-analysis / M.N.Mavros,K.P. Economopoulos, V.G. Alexiou, T.M. Pawlik // JAMA Surg. - 2014. - 149 (6). Р. 565–574.134. Mazzaferro, V. Radiofrequency ablation of small hepatocellular carcinoma incirrhotic patients awaiting liver transplantation: a prospective study / V. Mazzaferro,C. Battiston, S. Perrone, A. Pulvirenti, E. Regalia, R. Romito, D.
Sarli, M. Schiavo,F. Garbagnati, A. Marchianò, C. Spreafico, T. Camerini, L. Mariani, R. Miceli,S. Andreola // Ann Surg. - 2004. - 240 (5). - Р. 900-909.135. Meyer, C.G. Liver transplantation for cholangiocarcinoma: results in 207patients / C.G. Meyer, I. Penn, L. James // Transplantation. - 2000.
- 69. - Р. 1633.136. Murakami, T. Ultrasonography, co mputed tomography and magnetic resonanceimaging of hepatocellular carcinoma: toward improved treatment decisions /T. Murakami, Y. Imai, M. Okada // Oncology. - 2011. - 81 (1). - Р. 86-99.137. Okuno, K. Multidisciplinary treatment for liver metastasis using cytokines /K.
Okuno, M. Yasutomi // Nihon Geka Gakkai Zasshi. - 2001. - №102(5). - P. 403-408.134138. Orcutt, S.T. Liver Resection and Surgical Strategies for Management of PrimaryLiver Cancer / S.T. Orcutt, D.A. Anaya // Cancer Control. - 2018. - 25(1).139. Ozkan, Z.G. Favorable survival time provided with radioembolization inhepatocellular carcinoma patients with and without portal vein thrombosis /Z.G. Ozkan, A.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
